LOGIN  |  REGISTER
C4 Therapeutics
Astria Therapeutics

Progyny Enhances Suite of Services with Acquisition of BenefitBump

January 28, 2025 | Last Trade: US$21.50 0.16 0.75

NEW YORK, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a transformative fertility, family building, and women’s health benefits solution, today announced the acquisition of BenefitBump, a comprehensive parental leave benefits navigation program for new and growing families. This addition enhances Progyny’s fertility and family building offering, extending the company's ability to further serve the needs of families on their journey from pregnancy to early childhood and beyond.

With 90% of parents seeking greater support to manage responsibilities at work and home, Progyny’s enhanced suite of solutions aims to reduce member stress, improve recruitment, return-to-work and retention rates, and foster proactive child and family health. By addressing gaps across the spectrum, from fertility to postpartum support and parental leave navigation, the company helps eliminate fragmentation and enhances multi-dimensional outcomes for families.

"The acquisition of BenefitBump extends our ability to provide compassionate and dedicated support to give members more confidence along their parenting journey," said Pete Anevski, Chief Executive Officer, Progyny. "BenefitBump’s high-touch, guided support integrates seamlessly into our existing patient care model and aligns with our commitment to improving member well-being through a higher standard of care."

Alongside the offerings Progyny is known for across preconception, fertility, pregnancy, postpartum, and menopause, the enhanced suite of services will include:

  • Clinical social worker-led parental wellness program
  • Comprehensive parental leave and benefits navigation
  • Care and resource navigation for child behavior concerns and neurodiverse care
  • Clinician-facilitated peer support groups

“Navigating employee benefits and leave programs is complex and adds unnecessary stress for families. Every new parent will experience leave, yet it has been an underserved area. BenefitBump was built by listening to the challenges and needs of parents, with the goal of easing their anxiety and ensuring employers and employees get the most value from family support investments,” said Scott Liebman, Founder, BenefitBump. “We’re thrilled to join Progyny, an innovator and leader in the family building space, and together provide the holistic support that families deserve.”

For more information about Progyny visit www.progyny.com.

About Progyny

Progyny (Nasdaq: PGNY) is a transformative fertility, family building and women’s health benefits solution, trusted by the nation’s leading employers, health plans and benefit purchasers. We envision a world where everyone can realize their dreams of family and ideal health. Our outcomes prove that comprehensive, inclusive, and intentionally designed solutions simultaneously benefit employers, patients and physicians. 

Our benefits solution empowers patients with concierge support, coaching, education, and digital tools; provides access to a premier network of fertility and women's health specialists who use the latest science and technologies; drives optimal clinical outcomes; and reduces healthcare costs.  

Headquartered in New York City, Progyny has been recognized for its leadership and growth as a TIME100 Most Influential Company, CNBC Disruptor 50, Modern Healthcare's Best Places to Work in Healthcare, Forbes' Best Employers, Financial Times Fastest Growing Companies, Inc. 5000, Inc. Power Partners, and Crain's Fast 50 for NYC. For more information, visit www.progyny.com

For Further Information, Please Contact:

Investors:
James Hart
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media:
Alexis Ford
This email address is being protected from spambots. You need JavaScript enabled to view it.

Terns Pharmaceuticals

Stock Quote

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page